Drug intelligence / Profile preview

Shenwei Ningyu

Development stage: Phase 3
Lead developer: Guangdong Siji Pharmaceutical
Administration: Oral

Overview

Shenwei Ningyu is a Traditional Chinese Medicine (TCM) formulation developed by Guangdong Laida Pharmaceutical for the treatment of major depressive disorder (MDD). It is specifically indicated for patients diagnosed with the "Qi and Yin deficiency" syndrome (气阴两虚证) according to TCM principles. The drug is currently in Phase III clinical development in China, with studies such as CTR20171668 evaluating its efficacy and safety in this patient population. As a botanical product, it likely utilizes a multi-target approach characteristic of herbal medicine to alleviate depressive symptoms and restore physiological balance.

Brand names: Shenwei NingyuNingyu
Other names: Shenwei Ningyu Tablet参味宁郁片

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on Shenwei Ningyu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenwei Ningyu.